Phaseline

Companies › Kymera Therapeutics

Kymera Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 5 registered trials: 3 Phase 2, 2 Phase 1; Other, Immunology, Respiratory; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
KT-621
Cereblon E3 ubiquitin ligase ligand (CRBN-binding degrader)
–Phase 2Atopic Dermatitis; Eosinophilic Asthma; Asthma (Diagnosis); Healthy ParticipantsApr 2027
KT-579–Phase 1Healthy Participants–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07412288KT-579Phase 1Healthy ParticipantsOtherAug 2026
NCT07823205KT-621Phase 1Healthy ParticipantsOtherApr 2027
NCT07217015KT-621Phase 2Atopic DermatitisImmunologyJun 2027
NCT07323654KT-621Phase 2Eosinophilic AsthmaRespiratoryDec 2027
NCT07677059KT-621Phase 2Asthma (Diagnosis)RespiratoryDec 2028

From the company's SEC filings

Cash and short-term investments of $971m on 2026-09-30; operating cash outflow about $296m a year; runway about 39 months at that burn, to Jan 2030; 3 of 3 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 11 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Shattuck Labs QED Therapeutics, a BridgeBio company Oruka Therapeutics Shanghai Synvida Biotechnology Monte Rosa Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.